NCT05650021Completed
Rectal Spacer for Prostate Cancer Radiation Image Guidance
Radiopaque Hydrogel Rectal Spacer for Prostate Cancer Radiation Image Guidance
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
The purpose of the study is to determine if a radiopaque hydrogel rectal spacer, SpaceOAR Vue®, can be used in place of fiducial markers when aligning patients for radiotherapy. The investigator hypothesizes that the alignment of the patient based on the rectal spacer will be similar to the alignment of the patient with fiducial markers.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 17 (actual)
- First submitted
- 6 Dec 2022
- Start date
- 8 Mar 2024
- Primary completion date
- 15 Sept 2025
- Lead sponsor
- Milton S. Hershey Medical Center
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT05650021
What you commit to
- Study type: Interventional
- Participants enrolled: 17
- From 8 Mar 2024 to the primary completion date, 15 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior prostatectomy
Other illness
- Extracapsular extension of prostate cancer
Who the study is looking for
- To be eligible for the study, you must have already had SpaceOAR and fiducial markers placed before undergoing prostate radiotherapy, or you should have a plan to have them placed.
- Untreated cT1 - cT3 prostate cancer
Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Penn State Cancer Institute Coordinator of this site? Confirm its status | Hershey | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.